



KDCA

Korea Disease Control and Prevention Agency

# Updates on COVID-19 in Republic of Korea

7 May 2021

## COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021) (n, %)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
<b>Eligible</b>	<b>6,323,395</b>	1,110,445	451,289	290,846	314,018	178,095	169,049	99,535	26,598
<b>New (1st dose)</b>	<b>41,965</b>	11,021	2,580	2,064	2,139	1,807	1,000	795	275
<b>New (2nd dose)</b>	<b>73,491</b>	11,715	2,683	2,375	2,850	1,792	1,980	804	482
<b>Total (1st dose)</b>	<b>3,608,616</b>	574,583	226,761	154,034	178,383	113,910	102,937	60,585	18,042
<b>Total (2nd dose)</b>	<b>397,190</b>	59,707	20,948	15,629	26,240	13,469	9,789	11,741	3,767
<b>% (1st dose)</b>	<b>57.1</b>	51.7	50.2	53.0	56.8	64.0	60.9	60.9	67.8
<b>% (2nd dose)</b>	<b>6.3</b>	5.4	4.6	5.4	8.4	7.6	5.8	11.8	14.2

  

	Province								
	Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam	Jeju
<b>Eligible</b>	1,341,856	251,559	221,370	308,926	300,419	336,532	412,692	428,342	81,824
<b>New (1st dose)</b>	7,110	1,640	1,306	1,142	1,725	2,495	2,319	1,640	907
<b>New (2nd dose)</b>	12,319	3,923	3,171	4,680	3,140	6,559	6,534	7,730	754
<b>Total (1st dose)</b>	788,945	144,469	134,011	176,661	184,469	215,260	232,569	258,328	44,669
<b>Total (2nd dose)</b>	66,864	22,344	21,735	19,756	22,543	24,263	21,875	27,242	9,278
<b>% (1st dose)</b>	58.8	57.4	60.5	57.2	61.4	64.0	56.4	60.3	54.6
<b>% (2nd dose)</b>	5.0	8.9	9.8	6.4	7.5	7.2	5.3	6.4	11.3

※ Figures subject to correction recording update

## Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total AEFI <sup>(a)</sup>	General AEFI <sup>(b)</sup>	Serious AEFI <sup>(c)</sup>			
					Subtotal	Death <sup>①</sup>	Anaphylaxis suspected <sup>②</sup>	Major AEFI <sup>③</sup>
<b>Total</b>	<b>New</b>	<b>4,005,806</b>	<b>611</b>	<b>566</b>	<b>45</b>	<b>4</b>	<b>4</b>	<b>37</b>
	<b>Total</b>		<b>18,871</b>	<b>18,191</b>	<b>680</b>	<b>92</b>	<b>185</b>	<b>403</b>
<b>AstraZeneca</b>	<b>New</b>	<b>1,960,799</b>	<b>421</b>	<b>394</b>	<b>27</b>	<b>3</b>	<b>3</b>	<b>21</b>
	<b>Total</b>		<b>15,886</b>	<b>15,430</b>	<b>456</b>	<b>50</b>	<b>149</b>	<b>257</b>
<b>Pfizer</b>	<b>New</b>	<b>2,045,007</b>	<b>190</b>	<b>172</b>	<b>18</b>	<b>1</b>	<b>1</b>	<b>16</b>
	<b>Total</b>		<b>2,985</b>	<b>2,761</b>	<b>224</b>	<b>42</b>	<b>36</b>	<b>146</b>

(a) Cases reported by healthcare institutions as suspected AEFI cases; does not indicate causal association

(b) Common symptoms following vaccination including redness, pain, swelling, muscle pain, fever, headache, chills, etc.

(c) Serious AEFI includes the following:

- ① Death,
- ② Anaphylaxis suspected (including anaphylactoid reactions)
- ③ Major AEFI: Adverse events of special interest (AESI), admission to ICU, critical condition, permanent disability/sequelae/etc.



KDCA

Korea Disease Control and Prevention Agency

# Updates on COVID-19 in Republic of Korea

7 May 2021

## Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		525 (100)	126,044 (100)	243.11
Sex	Male	258 (49.14)	62,800 (49.82)	242.82
	Female	267 (50.86)	63,244 (50.18)	243.39
Age	80 or above	11 (2.10)	5,447 (4.32)	286.80
	70-79	30 (5.71)	9,049 (7.18)	250.87
	60-69	79 (15.05)	19,349 (15.35)	304.98
	50-59	106 (20.19)	23,336 (18.51)	269.25
	40-49	70 (13.33)	18,728 (14.86)	223.24
	30-39	69 (13.14)	17,047 (13.52)	241.97
	20-29	76 (14.48)	18,747 (14.87)	275.43
	10-19	52 (9.90)	8,849 (7.02)	179.11
0-9	32 (6.10)	5,492 (4.36)	132.38	

\* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

## Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		9 (100)	1,860 (100)	1.48	162 (100)
Sex	Male	5 (55.56)	925 (49.73)	1.47	96 (59.26)
	Female	4 (44.44)	935 (50.27)	1.48	66 (40.74)
Age	80 or above	4 (44.44)	1,026 (55.16)	18.84	42 (25.93)
	70-79	3 (33.33)	530 (28.49)	5.86	63 (38.89)
	60-69	2 (22.22)	218 (11.72)	1.13	32 (19.75)
	50-59	0 (0.00)	62 (3.33)	0.27	15 (9.26)
	40-49	0 (0.00)	14 (0.75)	0.07	7 (4.32)
	30-39	0 (0.00)	7 (0.38)	0.04	3 (1.85)
	20-29	0 (0.00)	3 (0.16)	0.02	0 (0.63)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)	

\* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

## AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.24.	4.25.	4.26.	4.27.	4.28.	4.29.	4.30.	5.1	5.2.	5.3.	5.4.	5.5.	5.6.	5.7.
<b>Total</b>	136	136	132	156	160	157	164	174	170	164	162	173	172	162

\* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)